# ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo

Study · id `cardio:ct-nct05070260` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05070260](<https://clinicaltrials.gov/study/NCT05070260>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05070260

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 438 participants.

## Technical summary

Registry record NCT05070260. Randomized; triple masking; primary purpose treatment. Start 2021-09-23 (actual); primary completion 2024-04-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 438 participants (enrolled count; ClinicalTrials.gov record NCT05070260, source copy `cardio:ctgov-nct05070260-2024-07-03`, retrieved 2026-10-26)
- Started: 2021-09-23 (actual) (ClinicalTrials.gov record NCT05070260, source copy `cardio:ctgov-nct05070260-2024-07-03`, retrieved 2026-10-26)
- Primary completion: 2024-04-30 (actual) (ClinicalTrials.gov record NCT05070260, source copy `cardio:ctgov-nct05070260-2024-07-03`, retrieved 2026-10-26)
- Completion: 2024-04-30 (actual) (ClinicalTrials.gov record NCT05070260, source copy `cardio:ctgov-nct05070260-2024-07-03`, retrieved 2026-10-26)
- Countries: United States; Germany (ClinicalTrials.gov record NCT05070260, source copy `cardio:ctgov-nct05070260-2024-07-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05070260-2024-07-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
- Acronym: ACTISAVE
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Intravenous glenzocimab (ACT017) 1000 mg
- Intervention (Drug): Intravenous Placebo
- Lead sponsor: Acticor Biotech
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: a7e0cf7d42b0bc97c25d244125e67b21c8fd4b503bb01d769eab38e244aa6470
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
